Skip to content
Screener

Incyte INCY Common Stock Par Value Per Share

Common Stock Par Value Per Share at other companies

Gilead Sciences logo
Gilead SciencesGILD
$0.000.0%
Geron logo
GeronGERN
$0.00
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$0.000.0%
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
$0.000.0%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$0.000.0%
Exelixis logo
ExelixisEXEL
$0.000.0%

Other financials

Income statement

See full
Revenue$1.7B+37.7%
Gross profit$1.6B+38.0%
Operating income$697.9M+31.6%
Net income$585.6M+44.6%
EPS (diluted)$2.81+37.7%

Balance sheet

See full
Cash & equivalents$4.0B+104%
Total debt$38.3M-9.8%
Total equity$6.3B+52.1%
Total assets$7.9B+35.2%

Cash flow

See full
Operating cash flow$507.7M+1,035%
CapEx$1.6M-43.5%
Free cash flow$509.3M+1,069%

Valuation

See full
Market cap$24B+58.2%
Enterprise value$20.05B+51.3%
P/E14.9×-2.5×
P/S4.1×+0.8×

Profitability

See full
Gross margin92.6%-0.3pp
Operating margin30.6%+4.8pp
Net margin27.7%+8.7pp
FCF margin34%+12.3pp

Returns & leverage

See full
Return on equity30.7%+6.4pp
Debt / equity0.0×
Current ratio4.6×+1.7×

Where this comes from

Reported directly by Incyte in its filing.

Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.

The source filing: Incyte’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 4:02 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000879169-26-000056
Line itemJune 30,2026December 31,2025*
Commitments and contingencies (Note 15)
Stockholders’ equity:
Preferred Stock, $0.001 par value; 5,000,000 shares authorized; none issued or outstanding
Common Stock, $0.001 par value; 400,000,000 shares authorized; 200,977,687 and 198,460,009 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively201198
Additional paid-in capital5,221,8044,928,049
Accumulated other comprehensive income19,71825,462
Retained earnings1,102,704213,769
Total stockholders’ equity6,344,4275,167,478

Item 1. Financial Statements

FAQ

What is Incyte's common stock par value per share?
Incyte (INCY) reported common stock par value per share of $0.00 in Q2 2026.
How has Incyte's common stock par value per share changed year-over-year?
Incyte's common stock par value per share decreased by 0.0% year-over-year, from $0.00 to $0.00.
What is the long-term trend for Incyte's common stock par value per share?
Over 4 years (2021 to 2025), Incyte's common stock par value per share has grown at a 0.0% compound annual growth rate (CAGR), from $0.00 to $0.00.
What does common stock par value per share mean?
The par value of common stock is the arbitrary legal value assigned to each share of common stock at the time of issuance. It is a legacy accounting requirement that has little impact on the actual market value or trading price of the shares.

Ask your AI about Incyte's common stock par value per share.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude